gi-hepatology oncology
irAE Hepatitis Grading (CTCAE)
CTCAE v5.0 grading of immune-related adverse event (irAE) hepatitis from checkpoint inhibitor immunotherapy. Guides management decisions including corticosteroid dosing and immunotherapy interruption.
References
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Remdesivir · Antiviral — RNA Polymerase Inhibitor (COVID-19 / Hepatitis)
- Bulevirtide · Hepatitis D virus entry inhibitor
- Ipilimumab (Specialist drug) · Anti-CTLA-4 monoclonal antibody (immune checkpoint inhibitor)
- Nivolumab (Specialist drug) · Anti-PD-1 immune checkpoint inhibitor
- Pembrolizumab · Anti-PD-1 monoclonal antibody (immune checkpoint inhibitor)
- Atezolizumab · Anti-PD-L1 Monoclonal Antibody — Immune Checkpoint Inhibitor (Specialist Oncology Drug)
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.